What did @highvibemari actually say?
The creator says she lost 33 pounds over six months using "compound semaglutide" (she actually says "Compostemic Luteide" in the video, which is a mispronunciation) sourced from a telehealth platform called WeightCare. She calls it a life-changing medication, describes WeightCare as connecting patients with "specialists and prescribers," and uses a referral code at checkout. That last part matters: this is a sponsored post, labeled with #weightcarepartner, which means her experience is being shared in a commercial context. That does not make her results false, but it is context you deserve to have before you take her recommendation at face value.
Her core claims are: compound semaglutide works for weight loss, her personal results were 33 pounds in six months, and WeightCare is a legitimate way to access GLP-1 medication. We can actually evaluate those.
Does the science back this up?
On the core claim, yes, the evidence for semaglutide and weight loss is genuinely strong. The STEP 1 trial (Wilding et al., 2021, New England Journal of Medicine) showed that adults on 2.4mg weekly semaglutide lost an average of 14.9% of body weight over 68 weeks versus 2.4% on placebo. A 33-pound loss from a starting weight of 197 pounds is about 16.8%, which is above the trial average but not outside the range of real-world outcomes.
The more complicated question is whether compound semaglutide produces the same results as brand-name Wegovy. The FDA has stated clearly that compounded drugs are not FDA-approved and are not proven to be equivalent to their brand-name counterparts. There is no published head-to-head trial comparing compounded semaglutide to Wegovy. Her results are plausible, but attributing them specifically to a compounded formulation with the same confidence as a brand-name drug is not something the evidence supports.
What did they get wrong (or right)?
She got the general weight loss potential right. Semaglutide is one of the most studied anti-obesity medications available, and a 33-pound loss over six months is consistent with what clinical data shows is achievable for some patients.
What she got wrong, or at least incomplete, is the framing around compound semaglutide specifically. Saying "compound semaglutide has literally changed my life" without acknowledging that compounded versions carry real regulatory caveats is a gap. The FDA issued warnings in 2024 about compounded semaglutide products, citing concerns about dosing errors, contamination risk, and the use of salt forms like semaglutide sodium that are not the same as the active ingredient in Wegovy or Ozempic. She presents the compound version as interchangeable with the broader clinical evidence, and it is not.
She also does not mention side effects. The STEP trials consistently documented nausea, vomiting, and gastrointestinal issues in a significant portion of participants. A before-and-after post with zero mention of adverse effects is a selective presentation of the experience.
What should you actually know?
If you are considering a GLP-1 medication, here is what the science actually says. Semaglutide works for weight loss in clinical trials, full stop. But "compound semaglutide" is a different regulatory and quality category than FDA-approved Wegovy. The FDA removed compounded semaglutide from its shortage list in early 2025, which means most compounding pharmacies are no longer legally permitted to produce it under the shortage exemption.
A telehealth platform connecting you with a prescriber is a legitimate care model, and several peer-reviewed analyses have found telehealth-delivered obesity treatment to be effective (Tchang et al., 2023, Obesity). But the specific compound product, the prescribing practices, and the pharmacy quality vary widely. Before starting any GLP-1 medication through any platform, you should verify the pharmacy is NABP-accredited, confirm the prescriber is licensed in your state, and have a real clinical conversation about your cardiovascular history, since semaglutide carries a boxed warning about thyroid C-cell tumors in rodent studies and is contraindicated in patients with a personal or family history of medullary thyroid carcinoma.
Sponsored content is not inherently dishonest. But it does mean the person sharing it has a financial interest in your decision. Weight the evidence, not just the before-and-after photo.